Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421963 · ClinicalTrials.gov registry record · Phase 3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
A Phase 3 study of Breast Cancer and Ovarian Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT04421963 is a Phase 3 study of Breast Cancer and Ovarian Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 185 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04421963, a Phase 3 study of Breast Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (20)
Other
- Research Site - Leuven
- Research Site - Namur
- Research Site - Rio de Janeiro
- Research Site - Plovdiv
- Research Site - Plovdiv
- Research Site - Sofia
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
- Research Site - Willow Grove
New Jersey
- Research Site - Basking Ridge
- Research Site - Hackensack
New York
- Research Site - New York
- Research Site - The Bronx
Florida
- Research Site - Boca Raton
Maryland
- Research Site - Towson
Michigan
- Research Site - Detroit
Minnesota
- Research Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2027-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04421963
The ClinicalTrials.gov registry entry for NCT04421963 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT04421963 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04421963 about?
NCT04421963 is a clinical study titled "Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib". The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
What is the current status of trial NCT04421963?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2020-08-04. Estimated completion is 2027-04-06.
What conditions does trial NCT04421963 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT04421963?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT04421963?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04421963 being conducted?
This trial has 20 study locations across Florida, Maryland, Michigan, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.